Results 91 to 100 of about 25,475 (182)
Experimental hypothermia by cold air: a randomized, double-blind, placebo-controlled crossover trial
Background Accidental hypothermia is associated with high morbidity and mortality. Research on treatment strategies for accidental hypothermia is complicated by the low incidence and heterogeneous patient population.
Ane M. Helland +6 more
doaj +1 more source
Deviation from the treatment strategy under investigation occurs in many clinical trials. We term this intervention deviation. Per-protocol analyses are widely adopted to estimate a hypothetical estimand without the occurrence of intervention deviation. Per-protocol by censoring is prone to selection bias when intervention deviation is associated with
Xuan, J. +7 more
openaire +3 more sources
BackgroundProgression-free survival (PFS) is a crucial endpoint in cancer drug research. Clinician-confirmed cancer progression, namely real-world PFS (rwPFS) in unstructured text (ie, clinical notes), serves as a reasonable surrogate for real-world ...
Gowtham Varma +16 more
doaj +1 more source
Background Treatment switching in randomized clinical trials introduces challenges in performing causal inference. Intention To Treat (ITT) analyses often fail to fully capture the causal effect of treatment in the presence of treatment switching ...
Amani Al Tawil +3 more
doaj +1 more source
Reconstructing Pseudo Individual Patient-Level Data From Published Survival Curves in Cardiovascular Trials. [PDF]
Tong G, Li F.
europepmc +1 more source
A note on rank-preserving structural failure time models to account for crossover. [PDF]
Torres-Saavedra PA +3 more
europepmc +1 more source
Reassessment of the Collaborative Normal-Tension Glaucoma Study: Statistical Evidence and Implications for Current Management. [PDF]
Killer HE, Pircher A, Stekhoven DJ.
europepmc +1 more source
While-alive regression analysis of composite survival endpoints. [PDF]
Fang X, Uno H, Li F.
europepmc +1 more source
Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies. [PDF]
Shitara K +9 more
europepmc +1 more source

